Product Code: GBIHC484MR
Epilepsy Therapeutics in Asia-Pacific Markets to 2024 - Uptake of Novel Therapies and Rising Awareness is Expected to Drive the Market Growth
Epilepsy is a chronic medical disorder or condition in which the brain is overactive, sending too many signals, usually resulting in unpredictable, unprovoked recurrent seizures that affect a variety of mental and physical functions. Epilepsy is the fourth most common neurological disorder, affecting more than 65 million individuals worldwide. Epilepsy can start at any age, but is most commonly diagnosed in people under 20 and people over 65. This is because some causes are more common in young people (such as difficulties at birth, childhood infections or accidents) and in older people (such as strokes that lead to epilepsy).
Epilepsy treatment has historically been dominated by gamma aminobutyric acid (GABA) modulators and sodium channel blockers, leaving a wide unmet need intact in a sizeable section of patients who do not respond to the existing treatment options. Historically there is a lack of potent disease modifying or curative drugs in the epilepsy therapeutic space. The dominant older generation AEDs had poor safety and tolerability profiles. Second generation AEDs with newer mechanisms of action; signaled a shift in this trend in the last decade with improved tolerability and efficacy.
Epilepsy market in the five major geographies in the Asia-Pacific (APAC) region (Australia, China, India, Japan and South Korea) is expected to increase at a compound annual growth rate (CAGR) of 3.5% to reach $1.75 billion in 2024. The value of the market is expected to grow more rapidly in India and China compared with the more developed markets, Japan and Australia. With a high prevalence, these two regions have large treatment populations, which are expected to grow further due to better healthcare access and improvements in treatment gaps.
The late-stage pipeline contains promising therapies that have the potential to achieve approval and launch during the forecast period. These drugs are under development with novel mechanisms of actions that are not conventional in the epilepsy market and are expected to provide greater efficacy and safety than previous AEDs. The launch and uptake of these new pipeline therapies with better efficacy are expected to drive APAC market growth.
- The APAC epilepsy market will be valued at $1.7 billion in 2024, growing from $1.4 billion in 2017 at a CAGR of 3.5%.
- How will the approval of Cenobamate for treatment-resistant epilepsy affect the competitive landscape, with no therapy currently available to address this patient subset?
- The epilepsy market is crowded with cheap, generic, "me-too" drugs. What are the main barriers a new therapy faces when entering the epilepsy market?
- The pipeline for epilepsy therapy is not diverse in terms of molecule type and molecular targets.
- How have the late-stage therapies performed in clinical trials?
- The level of unmet need in the epilepsy market is high. Will the pipeline drugs fulfill these unmet needs?
- The market forecasts indicate that India and China will contribute the most to the APAC market.
- How will the annual cost of therapy and market size vary between the five assessed APAC markets?
- How will the growing population affect the market?
- How will the various drivers and barriers influence the market over the forecast period?
- Licensing deals are the most common form of strategic alliance in epilepsy, with total deal values ranging from under $0.1m to over $820m.
- How do deal frequency and value compare between target families and molecule types?
Reasons to buy
- This report will enable you to:
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the epilepsy market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the epilepsy pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict epilepsy market growth in the five assessed APAC markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the epilepsy deals landscape by analyzing trends in licensing and co-development deals.
Table of Contents
1 Table of Contents 5
- 1.1 List of Tables 8
- 1.2 List of Figures 8
2 Introduction 10
- 2.1 Disease Introduction 10
- 2.2 Epidemiology 10
- 2.3 Disease Classification 11
- 2.4 Symptoms 13
- 2.5 Etiology and Pathophysiology 14
- 2.5.1 Etiology 14
- 2.5.2 Pathophysiology 15
- 2.6 Diagnosis 17
- 2.7 Prognosis 20
- 2.8 Treatment Guidelines and Options 21
- 2.8.1 Treatment Options 21
3 Marketed Products 28
- 3.1 Overview 28
- 3.1.1 Aptiom/Zebinix (Eslicarbazepine acetate) - BIAL-Portela 29
- 3.1.2 Banzel/Inovelon (Rufinamide) - Novartis 30
- 3.1.3 Briviact (Brivaracetam) - UCB 31
- 3.1.4 Fycompa (perampanel) - Eisai 32
- 3.1.5 Keppra (levetiracetam) - UCB 34
- 3.1.6 Lyrica (pregabalin) - Pfizer 36
- 3.1.7 Vimpat (lacosamide) - UCB 37
- 3.1.8 Lamictal (lamotrigine) - GSK 39
- 3.1.9 Epidiolex (Cannabidiol) - GW Pharmaceuticals 40
- 3.1.10 Older Generation AEDs 41
- 3.2 Comparative Efficacy and Safety of Marketed Product 42
4 Pipeline Analysis 44
- 4.1 Overview 44
- 4.2 Pipeline Distribution by Stage of Development, Molecule Type, Route of Administration and Program Type 44
- 4.3 Pipeline Distribution by Molecular Target 45
- 4.4 Promising Pipeline Candidates 48
- 4.4.1 Fintepla (low-dose fenfluramine Hydrochloride/ZX-008) - Zogenix 48
- 4.4.2 Cenobamate (YKP3089) - SK Biopharmaceuticals 50
- 4.5 Comparative Efficacy and Safety of Pipeline Products 52
- 4.6 Product Competitiveness Framework 53
5 Clinical Trial Analysis 54
- 5.1 Failure Rate 54
- 5.1.1 Overall Failure Rate 54
- 5.1.2 Failure Rate by Phase and Molecule Type 55
- 5.1.3 Failure Rate by Phase and Molecular Target 55
- 5.2 Clinical Trial Size 56
- 5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 56
- 5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 57
- 5.2.3 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 58
- 5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 59
- 5.3 Clinical Trial Duration 60
- 5.3.1 Clinical Trial Duration by Molecule Type 60
- 5.3.2 Clinical Trial Duration by Molecular Target 61
- 5.4 Competitive Clinical Trials Metrics Analysis 62
6 Multi-scenario Forecast 64
- 6.1 Geographical Markets 64
- 6.2 Asia-Pacific Market 65
- 6.3 India 66
- 6.3.1 Treatment Usage Patterns 66
- 6.3.2 Annual Cost of Therapy 68
- 6.3.3 Market Size 69
- 6.4 China 70
- 6.4.1 Treatment Usage Patterns 70
- 6.4.2 Annual Cost of Therapy 71
- 6.4.3 Market Size 72
- 6.5 Australia 73
- 6.5.1 Treatment Usage Patterns 73
- 6.5.2 Annual Cost of Therapy 74
- 6.5.3 Market Size 75
- 6.6 South Korea 76
- 6.6.1 Treatment Usage Patterns 76
- 6.6.2 Annual Cost of Therapy 77
- 6.6.3 Market Size 78
- 6.7 Japan 79
- 6.7.1 Treatment Usage Patterns 79
- 6.7.2 Annual Cost of Therapy 80
- 6.7.3 Market Size 82
7 Drivers and Barriers 83
- 7.1 Drivers 83
- 7.1.1 Improved Economy and Affordability Boost the Market 83
- 7.1.2 Promising Pipeline Products that Target Unmet Needs for Epilepsy 83
- 7.1.3 Government-Sponsored Increased Awareness and Access to Healthcare will Improve Epilepsy Treatment 83
- 7.2 Barriers 84
- 7.2.1 Social Stigma and Lack Awareness to Hamper Low Diagnosis and Treatment Rates 84
- 7.2.2 Impending Patent Cliffs and Generic Erosion 84
- 7.2.3 Lack of Strong Patent Protection or Intellectual Property Rights. 84
8 Deals and Strategic Consolidations 85
- 8.1 Licensing Deals 85
- 8.1.1 Deals by Region and Value 85
- 8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 86
- 8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 87
- 8.2 Key Licensing Deals 90
- 8.3 Co-development Deals 91
- 8.3.1 Deals by Region and Value 91
- 8.3.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 92
- 8.3.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 93
- 8.4 Key Co-development Deals 96
9 Appendix 98
- 9.1 All Pipeline Drugs by Stage of Development 98
- 9.1.1 Discovery 98
- 9.1.2 Preclinical 99
- 9.1.3 IND/CTA-filed 103
- 9.1.4 Phase I 103
- 9.1.5 Phase II 104
- 9.1.6 Phase III 105
- 9.1.7 Pre-registration 106
- 9.2 Summary of Multi-scenario Market Forecasts to 2024 107
- 9.2.1 Asia-Pacific 107
- 9.2.2 India 107
- 9.2.3 China 107
- 9.2.4 Australia 108
- 9.2.5 South Korea 108
- 9.2.6 Japan 109
- 9.3 Bibliography 109
- 9.4 Abbreviations 114
- 9.5 Research Methodology 116
- 9.5.1 Secondary Research 117
- 9.5.2 Marketed Product Profiles 117
- 9.5.3 Late-Stage Pipeline Candidates 117
- 9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 117
- 9.5.5 Product Competitiveness Framework 118
- 9.5.6 Pipeline Analysis 118
- 9.5.7 Forecasting Model 119
- 9.5.8 Deals Data Analysis 119
- 9.6 Contact Us 120
- 9.7 Disclaimer 120